Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Details

Serval ID
serval:BIB_389289378560
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Journal
Leukemia
Author(s)
Kuendgen A., Nomdedeu M., Tuechler H., Garcia-Manero G., Komrokji R.S., Sekeres M.A., Della Porta M.G., Cazzola M., DeZern A.E., Roboz G.J., Steensma D.P., Van de Loosdrecht A.A., Schlenk R.F., Grau J., Calvo X., Blum S., Pereira A., Valent P., Costa D., Giagounidis A., Xicoy B., Döhner H., Platzbecker U., Pedro C., Lübbert M., Oiartzabal I., Díez-Campelo M., Cedena M.T., Machherndl-Spandl S., López-Pavía M., Baldus C.D., Martinez-de-Sola M., Stauder R., Merchan B., List A., Ganster C., Schroeder T., Voso M.T., Pfeilstöcker M., Sill H., Hildebrandt B., Esteve J., Nomdedeu B., Cobo F., Haas R., Sole F., Germing U., Greenberg P.L., Haase D., Sanz G.
ISSN
1476-5551 (Electronic)
ISSN-L
0887-6924
Publication state
Published
Issued date
29/06/2020
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.
Pubmed
Open Access
Yes
Create date
03/07/2020 17:32
Last modification date
21/07/2020 6:26
Usage data